Abstract
Purpose
To identify factors benefiting from computed tomography during hepatic arteriography (CTHA) in addition to dynamic CT studies at the preoperative evaluation of the hypervascularity of hepatocellular carcinoma (HCC).
Materials and Methods
We retrospectively divided 45 patients with HCC, who underwent both dynamic CT (dCT) and CTHA, into two groups based on the number of hypervascular HCCs identified on dCT and CTHA studies. In group A, the number of HCCs identified by dCT and CTHA was the same and additive CTHA had not been indicated. In group B, fewer HCCs were counted on dCT than on CTHA images, indicating that additive CTHA studies had been appropriate. We compared the patient characteristics, the serum alpha-fetoprotein level, and the tumor-liver contrast (TLC) of the main tumor on dCT scans of both groups. To identify factors alerting to the benefit of additional CTHA studies, we performed univariate logistic regression analysis. Statistically significant parameters were subjected to receiver operating characteristic analysis for obtaining the optimal cutoff value indicative of the benefit of CTHA.
Results
Univariate analysis identified only the TLC of the main tumor on dCT images as a significant factor for the benefit of CTHA images (P < 0.01). At the optimal cutoff value for the TLC of the main tumor on dCT images (15.9 Hounsfield units), the sensitivity and specificity for the benefit of CTHA were 85.0 and 92.0%, respectively.
Conclusion
Evaluation of the TLC of the main tumor on dCT scans identifies patients in whom additive CTHA studies are beneficial.
Similar content being viewed by others
References
Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63–70.
Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–10.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.
Takayama T. Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol. 2011;41:447–54.
Matsuda M, Fujii H, Kono H, Matsumoto Y. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer. J Hepatobiliary Pancreat Surg. 2001;8:353–9.
Matsumoto Y, Fujii H, Matsuda M, Kono H. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance. J Hepatobiliary Pancreat Surg. 2001;8:435–40.
Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999;86:1032–8.
Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005;242:252–9.
Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery. 2008;143:469–75.
The Japan Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma 2013. http://www.jsh.or.jp/English/guidelines_en/Guidelines_for_hepatocellular_carcinoma_2013.
Pugacheva O, Matsui O, Kozaka K, Minami T, Ryu Y, Koda W, et al. Detection of small hypervascular hepatocellular carcinomas by EASL criteria: comparison with double-phase CT during hepatic arteriography. Eur J Radiol. 2011;80:e201–6.
Hayashi M, Matsui O, Ueda K, Kawamori Y, Kadoya M, Yoshikawa J, et al. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol. 1999;172:969–76.
Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002;225:143–9.
Murakami T, Okada M, Hyodo T. CT versus MR imaging of hepatocellular carcinoma: toward improved treatment decisions. Magn Reson Med Sci. 2012;11:75–81.
Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256:806–16.
Miyayama S, Yamashiro M, Nagai K, Tohyama J, Kawamura K, Yoshida M, et al. Evaluation of tumor recurrence after superselective conventional transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison of computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging. Hepatol Res. 2016;46:890–8.
Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266:452–61.
Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014;271:426–34.
Motosugi U, Bannas P, Bookwalter CA, Sano K, Reeder SB. An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging. Radiology. 2016;279:93–102.
Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991;178:493–7.
Murakami T, Takamura M, Kim T, Hori M, Federle MP, Onishi H, et al. Double phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma. Eur J Radiol. 2005;54:246–52.
Jang HJ, Lim JH, Lee SJ, Park CK, Park HS, Do YS. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology. 2000;215:373–80.
Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
Tsurusaki M, Sugimoto K, Fujii M, Fukuda T, Matsumoto S, Sugimura K. Combination of CT during arterial portography and double-phase CT hepatic arteriography with multi-detector row helical CT for evaluation of hypervascular hepatocellular carcinoma. Clin Radiol. 2007;62:1189–97.
Ueda K, Matsui O, Kawamori Y, Nakanuma Y, Kadoya M, Yoshikawa J, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology. 1998;206:161–6.
Pathologic diagnosis of early hepatocellular carcinoma. A report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–64.
Gonen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001;221:763–7.
Baron RL. Understanding and optimizing use of contrast material for CT of the liver. AJR Am J Roentgenol. 1994;163:323–31.
Yanaga Y, Awai K, Nakayama Y, Nakaura T, Tamura Y, Funama Y, et al. Optimal dose and injection duration (injection rate) of contrast material for depiction of hypervascular hepatocellular carcinomas by multidetector CT. Radiat Med. 2007;25:278–88.
Nakaura T, Nagayama Y, Kidoh M, Nakamura S, Namimoto T, Awai K, et al. Low contrast dose protocol involving a 100 kVp tube voltage for hypervascular hepatocellular carcinoma in patients with renal dysfunction. Jpn J Radiol. 2015;33:566–76.
Sultana S, Awai K, Nakayama Y, Nakaura T, Liu D, Hatemura M, et al. Hypervascular hepatocellular carcinomas: bolus tracking with a 40-detector CT scanner to time arterial phase imaging. Radiology. 2007;243:140–7.
Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS. 1989;97:689–98.
Masuda T, Nakaura T, Funama Y, Higaki T, Kiguchi M, Imada N, et al. Aortic and Hepatic Contrast Enhancement During Hepatic-Arterial and Portal Venous Phase Computed Tomography Scanning: multivariate Linear Regression Analysis Using Age, Sex, Total Body Weight, Height, and Cardiac Output. J Comput Assist Tomogr. 2017;41:309–14.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
Murakami T, Kim T, Takamura M, Hori M, Takahashi S, Federle MP, et al. Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT. Radiology. 2001;218:763–7.
Ichikawa T, Kitamura T, Nakajima H, Sou H, Tsukamoto T, Ikenaga S, et al. Hypervascular hepatocellular carcinoma: can double arterial phase imaging with multidetector CT improve tumor depiction in the cirrhotic liver? AJR Am J Roentgenol. 2002;179:751–8.
Quaia E, D’Onofrio M, Cabassa P, Vecchiato F, Caffarri S, Pittiani F, et al. Diagnostic value of hepatocellular nodule vascularity after microbubble injection for characterizing malignancy in patients with cirrhosis. AJR Am J Roentgenol. 2007;189:1474–83.
Mandai M, Koda M, Matono T, Nagahara T, Sugihara T, Ueki M, et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol. 2011;84:499–507.
Marin D, Nelson RC, Samei E, Paulson EK, Ho LM, Boll DT, et al. Hypervascular liver tumors: low tube voltage, high tube current multidetector CT during late hepatic arterial phase for detection–initial clinical experience. Radiology. 2009;251:771–9.
Yanaga Y, Awai K, Nakaura T, Utsunomiya D, Funama Y, Date S, et al. Hepatocellular carcinoma in patients weighing 70 kg or less: initial trial of compact-bolus dynamic CT with low-dose contrast material at 80 kVp. AJR Am J Roentgenol. 2011;196:1324–31.
Kim KS, Lee JM, Kim SH, Kim KW, Kim SJ, Cho SH, et al. Image fusion in dual energy computed tomography for detection of hypervascular liver hepatocellular carcinoma: phantom and preliminary studies. Invest Radiol. 2010;45:149–57.
Lee JA, Jeong WK, Kim Y, Song SY, Kim J, Heo JN, et al. Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging. Eur J Radiol. 2013;82:569–76.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Awai receives research funding (more than 2,000,000 yen) from Toshiba Medical Systems Co., Ltd. The other authors have no conflicts of interest.
Ethical Approval
All procedures in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed Consent
This study was approved by our institutional review board; prior informed patient consent was waived because ours was a retrospective study.
Rights and permissions
About this article
Cite this article
Fuji, T., Nakamura, Y., Fukumoto, W. et al. Clinical Indication for Computed Tomography During Hepatic Arteriography (CTHA) in Addition to Dynamic CT Studies to Identify Hypervascularity of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 41, 618–627 (2018). https://doi.org/10.1007/s00270-017-1832-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-017-1832-9